-
How I treat … dyslipidaemia according to the cardiovascular risk profile
Descamps O.S. , Scheen A.J. , De Backer G. , Annemans L. , Muls E. , Belgian Atherosclerosis Society / Belgian Lipid Club
Rev Med Liege 2012, 67(4),167-173Abstract : The new guidelines from the European Athero-sclerosis Society and the European Society of Cardiology include a number of new items. Here we demonstrate their application in several different clinical examples. We focus on the 4 items most pertinent for medical practice: 1) the stratification of risk of cardiovascular disease into 4 categories (‘very high’, ‘high’, ‘moderate’ and ‘low risk’), involving —for primary prevention cases— the use of the SCORE table, which has been calibrated for Belgium and where the risk can be adjusted according to HDL cholesterol and the presence of other risk factors; 2) the choice of more stringent therapeutic targets for LDL cholesterol (< 70 mg/dl for ‘very high’ risk patients, 100 mg/dl for ‘high’ risk patients and 115 mg/dl for patients at ‘moderate’ risk); 3) the choice of other therapeutic targets (non-HDL cholesterol and apolipoprotein B levels) for patients at ‘very high’ or ‘high’ risk with combined dyslipidaemia; and 4) follow-up of lipid parameters and muscular and hepatic enzymatic profiles.
